Trial Profile

A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAGE-324 (Primary)
Indications Essential tremor
Focus Therapeutic Use
Acronyms KINETIC
Sponsors Sage Therapeutics

Most Recent Events

22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
12 Apr 2021 According to a SAGE Therapeutics media release, the company will host a conference call and webcast today to discuss the KINETIC study topline results.
12 Apr 2021 According to a SAGE Therapeutics media release, full data from this KINETIC Study will be shared at future scientific forums and in publications.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com